KPIs & Operating Metrics(New)
Active Patients By RegionActive Patients By Region AnnualActive Patients TotalActive Patients Total, AnnualAsset Allocation By Category %Breakdown Of AssetsCost Of RevenuesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome Before Taxes By RegionLong Lived Assets By RegionLong Lived Assets By Region AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of RevenuePrescriptions Received By RegionPrescriptions Received By Region AnnualPrescriptions Received By Region Annual, TotalPrescriptions Received TotalProperty And Equipment, NetR&D And Clinical Trial Expenses By ProgramReceivables And Prepaid ExpensesRevenue By Customer'S LocationRevenue By Customer'S Location %Revenue By Customer'S Location AnnualRevenue By Customer'S Location Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

NovoCure (NVCR) Gross Profit (2023 - 2025)

NovoCure's Gross Profit history spans 13 years, with the latest figure at $135.1 million for Q1 2026.

  • On a quarterly basis, Gross Profit rose 16.01% to $135.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $507.1 million, a 5.72% increase, with the full-year FY2025 number at $488.5 million, up 4.37% from a year prior.
  • Gross Profit hit $135.1 million in Q1 2026 for NovoCure, up from $132.2 million in the prior quarter.
  • Over the last five years, Gross Profit for NVCR hit a ceiling of $135.1 million in Q1 2026 and a floor of $92.0 million in Q2 2023.
  • Historically, Gross Profit has averaged $111.5 million across 5 years, with a median of $112.4 million in 2022.
  • Biggest five-year swings in Gross Profit: decreased 18.09% in 2023 and later grew 26.25% in 2024.
  • Tracing NVCR's Gross Profit over 5 years: stood at $99.5 million in 2022, then rose by 1.69% to $101.2 million in 2023, then grew by 26.25% to $127.8 million in 2024, then grew by 3.44% to $132.2 million in 2025, then grew by 2.22% to $135.1 million in 2026.
  • Business Quant data shows Gross Profit for NVCR at $135.1 million in Q1 2026, $132.2 million in Q4 2025, and $122.5 million in Q3 2025.